Prestige Brings In New Management As It Consolidates CDMO Control

Prestige Biologics Gets New CEO As Prestige Biopharma Becomes Largest Shareholder

Prestige Biopharma says it is acting to “consolidate group competitiveness” by taking an increased share in Prestige Biologics, at the same time as a new CEO was appointed for the CDMO.

Percentage increase neon sign hand grab
Prestige Biopharma has grabbed a larger stake in Prestige Biologics • Source: Shutterstock

Prestige Biopharma has taken an increased and controlling stake in its Prestige Biologics contract development and manufacturing organization, at the same time as announcing that Duk-Hoon Hyun had been appointed as the unit’s new CEO.

Commenting on the increased shareholding in Prestige Biologics, Prestige Biopharma indicated that it would “become the largest shareholder of Prestige Biologics by acquiring new shares to secure a total of 24.88% of the CDMO company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business